deaths related to semaglutide reduces risk of all-cause death Weight loss drug Wegovy reduced

Consult physicians if pregnant, nursing, or on diabetes meds, as GLP-1 modulation affects blood sugar

Science 359, 11511156

FDA approves weight loss drug Zepbound to treat obstructive sleep apnea The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea

GLP-1 receptor agonists have become a leading treatment option for weight management, with clinical trials showing an average weight loss of 15-22% over 68 weeks

Smart Labs Now is not responsible for health or life outcomes based on the information or recommendations provided

For those compounding the product, the FDA stated that it would not take action against 503A pharmacies until April 22, 2025, and would not take action against 503B outsourcing facilities until May 22, 2025